Biocell Center is an international company specializing in the cryopreservation and private banking of amniotic fluid stem cells. The company is headquartered in Italy with several international locations and is involved with numerous partnerships and research studies of amniotic fluid stem cells,.In 2008, Biocell Center opened the first amniotic fluid stem cell bank in the world, and in 2009 it opened the first amniotic fluid stem cell bank in the United States for private storage of stem cells obtained during genetic amniocentesisBiocell Center’s Italian headquarters in Busto Arsizio and Milan , are managed by company president Marco Reguzzoni and scientific director Giuseppe Simoni, and additional subsidiaries are located in Lugano , and Medford, Massachusetts - Boston area,Biocell Center is currently collaborating with several institutions, including Harvard University and the Caritas Christi Health Care hospital network , on several amniotic stem cell research projects. Wikipedia.
Kim C.-H.,Dongguk University |
Park C.D.,Biocell |
Lee A.-Y.,Dongguk University
Vaccine | Year: 2012
Atopic dermatitis (AD) is characterized by a chronic and replapsing skin disease with Th2-dominant allergic inflammation. Poly(I:C) has been shown to have immunopotentiator properties, but its effect on AD has not been examined. In this study, the immunomodulatory effects of poly(I:C), using dermatophagoides farinae (Df)-induced AD-like skin lesions in NC/Nga mice, were investigated. The clinical scores were reduced significantly by the treatment with poly(I:C) at 25 and 50 μg/mouse. Histological analysis of the skin also revealed that treatment of poly(I:C) at 25 and 50 μg/mouse significantly reduced the inflammatory cellular infiltrate, including mast cells and eosinophils. Moreover, poly(I:C) increased the level of IFN-γ, a Th1 cytokine, whereas decreasing that of selective Th2 cytokine both in vivo and in vitro. The levels of serum IgE and Th2 chemokines such as eotaxin, TARC, in spleen cells were also reduced by poly(I:C). These results suggest that poly(I:C) inhibit the development of Df-induced AD-like skin lesions in NC/Nga mice through regulation of the Th1/Th2 balance. Therefore, our results indicate that poly(I:C) might be a useful immunomodulatory agent for the treatment of human AD. © 2011 Elsevier Ltd.
Schwartz S.R.,International Research Services Inc |
Clinical Interventions in Aging | Year: 2012
Skin aging and its clinical manifestation is associated with altered molecular metabolism in the extracellular matrix of the dermis. In a pilot open-label study, we investigated the effect of a dietary supplement, BioCell Collagen® (BCC), which contains a naturally occurring matrix of hydrolyzed collagen type II and low-molecular-weight hyaluronic acid and chondroitin sulfate, in 26 healthy females who displayed visible signs of natural and photoaging in the face. Daily supplementation with 1 g of BCC for 12 weeks led to a significant reduction of skin dryness/scaling (76%, P = 0.002) and global lines/wrinkles (13.2%, P = 0.028) as measured by visual/tactile score. Additionally, a significant increase in the content of hemoglobin (17.7%, P = 0.018) and collagen (6.3%, P = 0.002) in the skin dermis was observed after 6 weeks of supplementation. At the end of the study, the increase in hemoglobin remained significant (15%, P = 0.008), while the increase in collagen content was maintained, but the difference from baseline was not significant (3.5%, P = 0.134). This study provides preliminary data suggesting that dietary supplementation with BCC elicits several physiological events which can be harnessed to counteract natural photoaging processes to reduce visible aging signs in the human face. A controlled study is necessary to verify these observations. © 2012 Schwartz and Park, publisher and licensee Dove Medical Press Ltd.
Effect of the novel low molecular weight hydrolyzed chicken sternal cartilage extract, biocell collagen, on improving osteoarthritis-related symptoms: A randomized, double-blind, placebo-controlled trial
Schauss A.G.,AIBMR Life Science Inc. |
Stenehjem J.,University of California at San Diego |
Park J.,Biocell |
Endres J.R.,AIBMR Life Science Inc. |
Clewell A.,AIBMR Life Science Inc.
Journal of Agricultural and Food Chemistry | Year: 2012
Osteoarthritis (OA) is a significant source of pain and disability. Current medical and surgical treatments can be costly and have serious side effects. The aim of this randomized, double-blind, placebo-controlled trial was to investigate the tolerability and efficacy of BioCell Collagen (BCC), a low molecular weight dietary supplement consisting of hydrolyzed chicken sternal cartilage extract, in the treatment of OA symptoms. Patients (n = 80) in the study had physician-verified evidence of progressive OA in their hip and/or knee joint. Joint pain had been present for 3 months or longer at enrollment, and pain levels were 4 or higher at baseline as assessed by Physician Global Assessment scores. Subjects were divided into two groups and administered either 2 g of BCC or placebo for 70 days. Other outcome measurements included visual analogue scale (VAS) for pain and Western Ontario and McMaster Universities Arthritis Index (WOMAC) scores taken on days 1, 35, and 70. The tolerability profile of the treatment group was comparable to that of the placebo. Intent-to-treat analysis showed that the treatment group, as compared to placebo, had a significant reduction of VAS pain on day 70 (p < 0.001) and of WOMAC scores on both days 35 (p = 0.017) and 70 (p < 0.001). The BCC group experienced a significant improvement in physical activities compared to the placebo group on days 35 (p = 0.007) and 70 (p < 0.001). BCC was well tolerated and found to be effective in managing OA-associated symptoms over the study period, thereby improving patient's activities of daily living. BCC can be considered a potential complement to current OA therapies. © 2012 American Chemical Society.
Biocell | Date: 2015-11-06
An improved isolator for collection, parametrical characterization and long-term preservation of samples containing stem cells comprises: a work chamber (
Biocell | Date: 2013-03-18
A method for obtaining a new antiviral compound with multiple action against many viruses, comprising modified highly purified yeast RNA, a pharmaceutical composition comprising such RNA, and a method for the treatment and prevention of viral disease comprising administering to a patient a composition comprising an amount effective to ameliorate the symptoms of viral disease of ribonucleic acid. The exogenous modified yeast RNA has a pronounced multiple anti-virus action in a wide range of concentrations. The modified yeast RNA is capable of inhibiting the reproduction of viruses from Orthomyxoviridae, Paramyxovirus, Hepatitis, Herpesviridae families, enterovirus and adenovirus. Also, the modified yeast RNA is capable of inhibiting the reproduction of influenza viruses, hepatitis C virus, genital herpes, human immunodeficiency virus and Coxsackie B virus.